Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc. Common Stock (MSLE) Stock Competitors & Peer Comparison
See (MSLE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MSLE | $7.59 | -11.33% | 10.3M | 3.11 | $2.57 | N/A |
| ONC | $289.94 | +1.62% | 30.4B | 114.54 | $2.48 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | N/A |
| DFTX | $18.30 | +1.78% | 1.8B | N/A | N/A | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LFMDP | $23.16 | +0.98% | 1B | -10.08 | -$2.26 | N/A |
| CGEM | $14.14 | +1.43% | 796.9M | -4.06 | -$3.32 | N/A |
| ATAI | $3.76 | -1.69% | 696M | -4.45 | -$0.83 | N/A |
| HITI | $2.46 | +1.23% | 216.1M | -5.35 | -$0.46 | N/A |
Stock Comparison
MSLE vs ONC Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, ONC has a market cap of 30.4B. Regarding current trading prices, MSLE is priced at $7.59, while ONC trades at $289.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas ONC's P/E ratio is 114.54. In terms of profitability, MSLE's ROE is -0.52%, compared to ONC's ROE of +0.07%. Regarding short-term risk, MSLE is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check ONC's competition here
MSLE vs WBA Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, MSLE is priced at $7.59, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas WBA's P/E ratio is -1.64. In terms of profitability, MSLE's ROE is -0.52%, compared to WBA's ROE of -0.39%. Regarding short-term risk, MSLE is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check WBA's competition here
MSLE vs DFTX Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, DFTX has a market cap of 1.8B. Regarding current trading prices, MSLE is priced at $7.59, while DFTX trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas DFTX's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to DFTX's ROE of -0.84%. Regarding short-term risk, MSLE is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check DFTX's competition here
MSLE vs HROWL Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, MSLE is priced at $7.59, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas HROWL's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, MSLE is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HROWL's competition here
MSLE vs HROWM Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, MSLE is priced at $7.59, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas HROWM's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to HROWM's ROE of -0.10%. Regarding short-term risk, MSLE is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HROWM's competition here
MSLE vs LFMDP Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, LFMDP has a market cap of 1B. Regarding current trading prices, MSLE is priced at $7.59, while LFMDP trades at $23.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas LFMDP's P/E ratio is -10.08. In terms of profitability, MSLE's ROE is -0.52%, compared to LFMDP's ROE of +2.82%. Regarding short-term risk, MSLE is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check LFMDP's competition here
MSLE vs CGEM Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, CGEM has a market cap of 796.9M. Regarding current trading prices, MSLE is priced at $7.59, while CGEM trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas CGEM's P/E ratio is -4.06. In terms of profitability, MSLE's ROE is -0.52%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, MSLE is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check CGEM's competition here
MSLE vs ATAI Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, ATAI has a market cap of 696M. Regarding current trading prices, MSLE is priced at $7.59, while ATAI trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas ATAI's P/E ratio is -4.45. In terms of profitability, MSLE's ROE is -0.52%, compared to ATAI's ROE of -1.08%. Regarding short-term risk, MSLE is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check ATAI's competition here
MSLE vs HITI Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, HITI has a market cap of 216.1M. Regarding current trading prices, MSLE is priced at $7.59, while HITI trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas HITI's P/E ratio is -5.35. In terms of profitability, MSLE's ROE is -0.52%, compared to HITI's ROE of -0.40%. Regarding short-term risk, MSLE is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HITI's competition here
MSLE vs LFMD Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, LFMD has a market cap of 191.6M. Regarding current trading prices, MSLE is priced at $7.59, while LFMD trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas LFMD's P/E ratio is -15.31. In terms of profitability, MSLE's ROE is -0.52%, compared to LFMD's ROE of +2.82%. Regarding short-term risk, MSLE is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check LFMD's competition here
MSLE vs LFLY Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, MSLE is priced at $7.59, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas LFLY's P/E ratio is -0.04. In terms of profitability, MSLE's ROE is -0.52%, compared to LFLY's ROE of +0.25%. Regarding short-term risk, MSLE is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check LFLY's competition here
MSLE vs YI Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, YI has a market cap of 57M. Regarding current trading prices, MSLE is priced at $7.59, while YI trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas YI's P/E ratio is -2.31. In terms of profitability, MSLE's ROE is -0.52%, compared to YI's ROE of +0.11%. Regarding short-term risk, MSLE is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check YI's competition here
MSLE vs PETS Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, PETS has a market cap of 52.6M. Regarding current trading prices, MSLE is priced at $7.59, while PETS trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas PETS's P/E ratio is -0.79. In terms of profitability, MSLE's ROE is -0.52%, compared to PETS's ROE of -1.22%. Regarding short-term risk, MSLE is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check PETS's competition here
MSLE vs POM Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, POM has a market cap of 42.4M. Regarding current trading prices, MSLE is priced at $7.59, while POM trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas POM's P/E ratio is -7.92. In terms of profitability, MSLE's ROE is -0.52%, compared to POM's ROE of +0.07%. Regarding short-term risk, MSLE is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check POM's competition here
MSLE vs RAD Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, MSLE is priced at $7.59, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas RAD's P/E ratio is -0.05. In terms of profitability, MSLE's ROE is -0.52%, compared to RAD's ROE of +2.76%. Regarding short-term risk, MSLE is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check RAD's competition here
MSLE vs RNTX Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, RNTX has a market cap of 34.2M. Regarding current trading prices, MSLE is priced at $7.59, while RNTX trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas RNTX's P/E ratio is -0.44. In terms of profitability, MSLE's ROE is -0.52%, compared to RNTX's ROE of -2.17%. Regarding short-term risk, MSLE is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check RNTX's competition here
MSLE vs KYNB Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, KYNB has a market cap of 28.2M. Regarding current trading prices, MSLE is priced at $7.59, while KYNB trades at $7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas KYNB's P/E ratio is -0.54. In terms of profitability, MSLE's ROE is -0.52%, compared to KYNB's ROE of -1.26%. Regarding short-term risk, MSLE is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check KYNB's competition here
MSLE vs MEDS Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, MSLE is priced at $7.59, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas MEDS's P/E ratio is -0.31. In terms of profitability, MSLE's ROE is -0.52%, compared to MEDS's ROE of -0.26%. Regarding short-term risk, MSLE is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check MEDS's competition here
MSLE vs CJJD Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, MSLE is priced at $7.59, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas CJJD's P/E ratio is -0.46. In terms of profitability, MSLE's ROE is -0.52%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, MSLE is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check CJJD's competition here
MSLE vs NEUP Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, NEUP has a market cap of 8.5M. Regarding current trading prices, MSLE is priced at $7.59, while NEUP trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas NEUP's P/E ratio is -6.58. In terms of profitability, MSLE's ROE is -0.52%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, MSLE is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check NEUP's competition here
MSLE vs SSY Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, MSLE is priced at $7.59, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas SSY's P/E ratio is -2.86. In terms of profitability, MSLE's ROE is -0.52%, compared to SSY's ROE of -0.18%. Regarding short-term risk, MSLE is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check SSY's competition here
MSLE vs HKPD Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, HKPD has a market cap of 6.7M. Regarding current trading prices, MSLE is priced at $7.59, while HKPD trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas HKPD's P/E ratio is 3.60. In terms of profitability, MSLE's ROE is -0.52%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, MSLE is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check HKPD's competition here
MSLE vs AIXC Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, AIXC has a market cap of 5.9M. Regarding current trading prices, MSLE is priced at $7.59, while AIXC trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas AIXC's P/E ratio is 0.40. In terms of profitability, MSLE's ROE is -0.52%, compared to AIXC's ROE of -0.73%. Regarding short-term risk, MSLE is less volatile compared to AIXC. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check AIXC's competition here
MSLE vs BGMSP Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, BGMSP has a market cap of 5.7M. Regarding current trading prices, MSLE is priced at $7.59, while BGMSP trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas BGMSP's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to BGMSP's ROE of -7.22%. Regarding short-term risk, MSLE is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check BGMSP's competition here
MSLE vs MDVL Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, MSLE is priced at $7.59, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas MDVL's P/E ratio is -0.05. In terms of profitability, MSLE's ROE is -0.52%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, MSLE is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check MDVL's competition here
MSLE vs ATNFW Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, MSLE is priced at $7.59, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas ATNFW's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to ATNFW's ROE of -1.93%. Regarding short-term risk, MSLE is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check ATNFW's competition here
MSLE vs NVOH Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, NVOH has a market cap of 1.9M. Regarding current trading prices, MSLE is priced at $7.59, while NVOH trades at $20.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas NVOH's P/E ratio is 11.15. In terms of profitability, MSLE's ROE is -0.52%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, MSLE is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check NVOH's competition here
MSLE vs BGMS Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, BGMS has a market cap of 1.7M. Regarding current trading prices, MSLE is priced at $7.59, while BGMS trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas BGMS's P/E ratio is -0.06. In terms of profitability, MSLE's ROE is -0.52%, compared to BGMS's ROE of -1.87%. Regarding short-term risk, MSLE is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check BGMS's competition here
MSLE vs AZNH Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, MSLE is priced at $7.59, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas AZNH's P/E ratio is 38.35. In terms of profitability, MSLE's ROE is -0.52%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, MSLE is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check AZNH's competition here
MSLE vs LFLYW Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, MSLE is priced at $7.59, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, MSLE's ROE is -0.52%, compared to LFLYW's ROE of +0.25%. Regarding short-term risk, MSLE is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check LFLYW's competition here
MSLE vs BIMI Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, MSLE is priced at $7.59, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas BIMI's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, MSLE is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check BIMI's competition here
MSLE vs IPXL Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, MSLE is priced at $7.59, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas IPXL's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, MSLE is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check IPXL's competition here
MSLE vs ESRX Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, MSLE is priced at $7.59, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas ESRX's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, MSLE is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check ESRX's competition here
MSLE vs POZN Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, POZN has a market cap of 0. Regarding current trading prices, MSLE is priced at $7.59, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas POZN's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to POZN's ROE of +0.61%. Regarding short-term risk, MSLE is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for MSLE.Check POZN's competition here
MSLE vs CPD Comparison March 2026
MSLE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSLE stands at 10.3M. In comparison, CPD has a market cap of 0. Regarding current trading prices, MSLE is priced at $7.59, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSLE currently has a P/E ratio of 3.11, whereas CPD's P/E ratio is N/A. In terms of profitability, MSLE's ROE is -0.52%, compared to CPD's ROE of N/A. Regarding short-term risk, MSLE is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for MSLE.Check CPD's competition here